Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Sci Rep ; 11(1): 13834, 2021 07 05.
Article in English | MEDLINE | ID: mdl-34226640

ABSTRACT

Transjugular intrahepatic portosystemic shunt (TIPS) is one of the main treatment options in patients with decompensated liver cirrhosis but is still associated with partly severe complications. For adequate patient selection, prognostic parameters are of crucial importance. The liver maximum capacity (LiMAx) breath test measures enzymatic liver function and could potentially represent an efficient prognostic marker. We therefore aimed to assess the role of LiMAx in predicting survival of TIPS patients in a prospective analysis. LiMAx was performed for patients who underwent TIPS implantation between October 2016 and February 2018. Associations with transplant-free survival after 24 weeks were assessed by logistic regression. A total number of 30 patients were included, of whom seven received liver transplantation (N = 2) or died (N = 5) during follow-up. LiMAx values after (P = 0.01, OR = 1.24, 95% CI = 1.04-1.47) and before (P = 0.03, OR 1.21, 95% CI = 1.02-1.43) TIPS implantation and MELD score (P = 0.03, OR = 0.79, 95% CI = 0.63-0.98) were significantly associated with transplant-free survival according to univariate logistic regression. In AUROC analysis, LiMAx at day one after TIPS (sensitivity 85.7%, specificity 78.3%, AUROC 0.85, cut-off ≤ 165 µg/kg/h), LiMAx value at the day before TIPS (sensitivity 100%, specificity 73.9%, AUROC 0.82, cut-off ≤ 205 µg/kg/h) and MELD score (sensitivity 71.4%, specificity 73.9%, AUROC 0.82, cut-off ≥ 15) had the highest prognostic accuracy. LiMAx values prior and after TIPS procedure seem to be good prognostic parameters regarding prediction of transplant-free survival of patients undergoing TIPS implantation.


Subject(s)
Hypertension, Portal/pathology , Liver Cirrhosis/therapy , Liver/enzymology , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Adult , Aged , Female , Humans , Hypertension, Portal/etiology , Hypertension, Portal/prevention & control , Liver/pathology , Liver Cirrhosis/diagnosis , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/pathology , Male , Maximal Voluntary Ventilation , Middle Aged , Patient Selection , Portasystemic Shunt, Transjugular Intrahepatic/standards , Prognosis
2.
Intern Emerg Med ; 16(6): 1519-1527, 2021 09.
Article in English | MEDLINE | ID: mdl-33400160

ABSTRACT

BACKGROUND AND AIMS: Patients with decompensated cirrhosis frequently require hospital admissions, which are associated with worse prognosis. The aim of this study was to analyze the effect of TIPS on the need for hospital care. Secondary objectives were to assess the clinical and biological impact of TIPS and to identify predictors of post-TIPS hospital care. METHODS: An observational, retrospective study of patients with decompensated cirrhosis treated with TIPS from January 2008 until March 2019. Exclusion criteria were TIPS placed for non-cirrhotic portal hypertension (PH) and patients referred from another hospital without prior or subsequent follow-up at our Unit. Hospital care, PH-related complications, and laboratory data were compared before and after TIPS. RESULTS: The final cohort comprised 104 patients (72% male) with a mean age of 60 (± 10) years. Follow-up from first decompensation until TIPS and that from procedure to study completion were 7 (4.2-9.8) and 20 (4.6-35.4) months, respectively. TIPS was indicated mainly for refractory ascites (50%) and variceal bleeding (39%). Hemodynamic and clinical success rates were 97% and 92%, respectively. The number of emergency department visits and hospital admissions decreased after the procedure (p < 0.001). Improvement was seen in MELD and Child-Pugh scores, renal function, hyponatremia, and anemia after TIPS. Variceal bleeding as the indication for TIPS (OR 0.047; 95 CI 0.006-0,39; p < 0.05) together with early creation of the shunt (stage 3 vs 5; p < 0.05) were associated with a reduction in risk of post-TIPS hospital care. CONCLUSION: TIPS is a safe and effective procedure that reduces hospital care burden by improving PH-related complications, hepatic, renal function, hyponatremia, and anemia. Variceal bleeding as the indication and early placement of the device were associated with a reduction in post-TIPS hospital care. These findings support a role for this treatment, predominantly in the early stages of cirrhosis.


Subject(s)
Cost of Illness , Fibrosis/surgery , Portasystemic Shunt, Transjugular Intrahepatic/instrumentation , Portasystemic Shunt, Transjugular Intrahepatic/standards , Aged , Female , Fibrosis/complications , Fibrosis/physiopathology , Hospitals/statistics & numerical data , Humans , Kaplan-Meier Estimate , Logistic Models , Male , Middle Aged , Portasystemic Shunt, Transjugular Intrahepatic/statistics & numerical data , Retrospective Studies , Treatment Outcome
3.
Gut ; 69(7): 1173-1192, 2020 07.
Article in English | MEDLINE | ID: mdl-32114503

ABSTRACT

These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the Liver Section of the BSG. The guidelines are new and have been produced in collaboration with the British Society of Interventional Radiology (BSIR) and British Association of the Study of the Liver (BASL). The guidelines development group comprises elected members of the BSG Liver Section, representation from BASL, a nursing representative and two patient representatives. The quality of evidence and grading of recommendations was appraised using the GRADE system. These guidelines are aimed at healthcare professionals considering referring a patient for a TIPSS. They comprise the following subheadings: indications; patient selection; procedural details; complications; and research agenda. They are not designed to address: the management of the underlying liver disease; the role of TIPSS in children; or complex technical and procedural aspects of TIPSS.


Subject(s)
Blood Vessel Prosthesis Implantation/methods , Blood Vessel Prosthesis , Hypertension, Portal/surgery , Portasystemic Shunt, Transjugular Intrahepatic/methods , Stents , Blood Vessel Prosthesis Implantation/standards , Esophageal and Gastric Varices/etiology , Esophageal and Gastric Varices/surgery , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/surgery , Humans , Portasystemic Shunt, Transjugular Intrahepatic/instrumentation , Portasystemic Shunt, Transjugular Intrahepatic/standards , Radiology, Interventional
4.
Medicina (Kaunas) ; 55(7)2019 Jul 03.
Article in English | MEDLINE | ID: mdl-31277322

ABSTRACT

Gastric varices are less common than esophageal varices, and their treatment is quite challenging. Gastric varix bleedings (GVB) occur less frequently than esophageal varix (EV) bleedings and represent 10% to 30% of all variceal bleedings. They are; however, more severe and are associated with high mortality. Re-bleeding may occur in 35% to 90% of cases after spontaneous hemostasis. GV bleedings represent a serious clinical problem compared with esophageal varices due to their location. Sclerotherapy and band ligation, in particular, are less effective. Based on the anatomic site and location, treatment differs from EV and is categorized into two groups (i.e., endoscopic or radiologic treatment). Surgical management is used less frequently. Balloon-occluded retrograde transvenous obliteration (BRTO) and cyanoacrylate are safe but there is a high risk of re-bleeding. Portal pressure elevates following BRTO and leads to worsening of esophageal varix pressure. Other significant complications may include hemoglobinuria, abdominal pain, fever, and pleural effusion. Shock and atrial fibrillation are major complications. New and efficient treatment modalities will be possible in the future.


Subject(s)
Esophageal and Gastric Varices/surgery , Treatment Outcome , Adhesives/standards , Adhesives/therapeutic use , Balloon Occlusion/methods , Balloon Occlusion/standards , Esophageal and Gastric Varices/etiology , Humans , Liver Diseases/complications , Liver Diseases/surgery , Portasystemic Shunt, Transjugular Intrahepatic/methods , Portasystemic Shunt, Transjugular Intrahepatic/standards
5.
Dig Liver Dis ; 49(2): 121-137, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27884494

ABSTRACT

The trans jugular intrahepatic Porto systemic shunt (TIPS) is no longer viewed as a salvage therapy or a bridge to liver transplantation and is currently indicated for a number of conditions related to portal hypertension with positive results in survival. Moreover, the availability of self-expandable polytetrafluoroethylene (PTFE)-covered endoprostheses has dramatically improved the long-term patency of TIPS. However, since the last updated International guidelines have been published (year 2009) new evidence have come, which have open the field to new indications and solved areas of uncertainty. On this basis, the Italian Association of the Study of the Liver (AISF), the Italian College of Interventional Radiology-Italian Society of Medical Radiology (ICIR-SIRM), and the Italian Society of Anesthesia, Analgesia and Intensive Care (SIAARTI) promoted a Consensus Conference on TIPS. Under the auspices of the three scientific societies, the consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Bergamo on June 4th and 5th, 2015. The final statements presented here were graded according to quality of evidence and strength of recommendations and were approved by an independent jury. By highlighting strengths and weaknesses of current indications to TIPS, the recommendations of AISF-ICIR-SIRM-SIAARTI may represent the starting point for further studies.


Subject(s)
Hypertension, Portal/surgery , Portasystemic Shunt, Transjugular Intrahepatic/standards , Ascites/complications , Drug-Eluting Stents , Esophageal and Gastric Varices/pathology , Gastrointestinal Hemorrhage/surgery , Humans , Italy , Liver Cirrhosis/complications , Liver Transplantation , Polytetrafluoroethylene , Portasystemic Shunt, Transjugular Intrahepatic/methods , Societies, Medical
10.
Dig Liver Dis ; 42(7): 462-7, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20036625

ABSTRACT

Since its first introduction in the 1980s, transjugular intrahepatic portosystemic shunt has played an increasingly important role in the management and treatment of the complications of portal hypertension. In 2005, the American Association for the Study of Liver Diseases published the Practice Guidelines for the use of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Since then, technical advances and new interesting data on transjugular intrahepatic portosystemic shunt have been presented in the literature. The present review focus on the applications of transjugular intrahepatic portosystemic shunt and examines more recent studies on this topic; the current guidelines on the use of transjugular intrahepatic portosystemic shunt are also discussed. From the data presented in the most recent publications, it has become increasingly clear that the recommendations stemming from the current guidelines need to be reviewed and updated in several points. Changes in the American Association for the Study of Liver Diseases Practice Guidelines are needed for both common indications (variceal bleeding and refractory ascites) as well as uncommon ones (i.e., Budd-Chiari syndrome and portal cavernoma). In addition, a relevant technical advance has been the introduction of the polytetrafluoroethylene-covered stents, which greatly improved the patency and clinical efficacy of transjugular intrahepatic portosystemic shunt. Consequently, new studies are required to re-assess the role of transjugular intrahepatic portosystemic shunt performed with new covered stents as compared with other strategies in the management of portal hypertension.


Subject(s)
Hemorrhage/prevention & control , Hypertension, Portal/therapy , Portasystemic Shunt, Transjugular Intrahepatic/standards , Budd-Chiari Syndrome/therapy , Esophageal and Gastric Varices , Humans , Practice Guidelines as Topic , Thrombosis/therapy
11.
Liver Int ; 26(5): 572-8, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16762002

ABSTRACT

OBJECTIVES: Parallel shunts (PS) are used in the management of transjugular intrahepatic portosystemic stent-shunt (TIPS) insufficiency, a major limitation of the technique. This study describes the natural history of PS, and uses them as a model to assess the role of host factors in the development of primary shunt insufficiency. METHODS: Out of 338 patients with TIPS, 40 (11.8%) patients required insertion of a PS. Baseline and follow-up data of these patients were collected. Regular shunt surveillance involved biannual clinic visits and transjugular portography. RESULTS: The non-PS group (group 1; n = 298) and the PS group (group 2; n = 40) had similar baseline demographic and disease characteristics. Index shunts of both groups and the PS produced a significant portal pressure gradient drop (P < 0.001), which was less in the index shunts of Group 2 (P < 0.02 for both). PS had similar cumulative shunt patency rates to those of the index shunts of Group 1, and both were greater than those of index shunts in Group 2 (P < 0.001 for both). The intervention rate (number of interventions/number of check portograms x 100) was similar for PS and the index shunts of Group 1 (38.7% and 43% respectively), but was significantly higher in the index shunts of Group 2 (85.6%; P < 0.01 for both). In Group 1 and Group 2, 144 patients (48.3%) and 21 patients (52.5%) died during follow-up after a median period of 23.4 and 8.9 months respectively. CONCLUSIONS: These findings do not support the hypothesis that shunt insufficiency is related to host factors.


Subject(s)
Portasystemic Shunt, Transjugular Intrahepatic/methods , Stents/standards , Adult , Aged , Biological Factors , Female , Follow-Up Studies , Humans , Male , Middle Aged , Portal Pressure , Portasystemic Shunt, Transjugular Intrahepatic/standards , Retrospective Studies , Survival Rate
16.
Arq Gastroenterol ; 38(1): 69-80, 2001.
Article in Portuguese | MEDLINE | ID: mdl-11586999

ABSTRACT

At the present time several therapeutic options are used for the treatment of bleeding esophageal varices in patients with portal hypertension. We will review the main medical publications on transjugular intrahepatic portosystemic shunt (TIPS), a procedure seldom used among us. TIPS works as a portocaval side-to-side shunt and decreases the risk of esophageal bleeding through lowering of the portal system pressure and a decrease of the portal hepatic pressure gradient. TIPS consists in the percutaneous insertion, through the internal jugular vein, of a metallic stent under fluoroscopic control in the hepatic parenchyma creating a true porta caval communication. There are several studies demonstrating the efficacy of TIPS, although only a few of them are randomized and control-matched to allow us to conclude that this procedure is safe, efficient and with a good cost benefit ratio. In this review, we search for the analysis of the TIPS utilization, its techniques, its major indications and complications. TIPS has been used in cases of gastroesophageal bleeding that has failed with pharmacologic or endoscopic treatment in patients Child-Pugh B and C. It can be used also as a bridge for liver transplantation. Others indications for TIPS are uncontrolled ascites, hepatic renal syndrome, and hepatic hydrothorax. The main early complications of TIPS using are related to the insertion site and hepatic encephalopathy and the stent occlusion is the chief late complication.


Subject(s)
Hypertension, Portal/therapy , Portasystemic Shunt, Transjugular Intrahepatic/standards , Ascites/complications , Ascites/therapy , Contraindications , Esophageal and Gastric Varices/complications , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Hemorrhage/therapy , Hemodynamics , Hepatorenal Syndrome/etiology , Hepatorenal Syndrome/therapy , Humans , Hydrothorax/etiology , Hydrothorax/therapy , Hypertension, Portal/complications , Liver Cirrhosis/complications , Liver Transplantation , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Portasystemic Shunt, Transjugular Intrahepatic/methods
18.
Arq. gastroenterol ; 38(1): 69-80, Jan.-Mar. 2001. tab
Article in Portuguese | LILACS | ID: lil-290421

ABSTRACT

At the present time several therapeutic options are used for the treatment of bleeding esophageal varices in patients with portal hypertension. We will review the main medical publications on transjugular intrahepatic portosystemic shunt (TIPS), a procedure seldom used among us. TIPS works as a portocaval side-to-side shunt and decreases the risk of esophageal bleeding through lowering of the portal system pressure and a decrease of the portal hepatic pressure gradient. TIPS consists in the percutaneous insertion, through the internal jugular vein, of a metallic stent under fluoroscopic control in the hepatic parenchyma creating a true porta caval communication. There are several studies demonstrating the efficacy of TIPS, although only a few of them are randomized and control-matched to allow us to conclude that this procedure is safe, efficient and with a good cost benefit ratio. In this review, we search for the analysis of the TIPS utilization, its techniques, its major indications and complications. TIPS has been used in cases of gastroesophageal bleeding that has failed with pharmacologic or endoscopic treatment in patients Child-Pugh B and C. It can be used also as a bridge for liver transplantation. Others indications for TIPS are uncontrolled ascites, hepatic renal syndrome, and hepatic hydrothorax. The main early complications of TIPS using are related to the insertion site and hepatic encephalopathy and the stent occlusion is the chief late complication.


Subject(s)
Humans , Hypertension, Portal/therapy , Portasystemic Shunt, Transjugular Intrahepatic/standards , Ascites/complications , Ascites/therapy , Esophageal and Gastric Varices/complications , Gastrointestinal Hemorrhage/surgery , Hemodynamics , Hepatorenal Syndrome/etiology , Hepatorenal Syndrome/therapy , Hydrothorax/etiology , Hydrothorax/therapy , Hypertension, Portal/complications , Liver Cirrhosis/complications , Liver Transplantation , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Portasystemic Shunt, Transjugular Intrahepatic , Portasystemic Shunt, Transjugular Intrahepatic/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...